Mark McClung
Plus aucun poste en cours
Fortune : 56 033 $ au 30/04/2024
Profil
Mark D.
McClung worked as the VP & General Manager-Global Oncology Commercial at Amgen, Inc. from 2015 to 2019.
He also worked as the Chief Commercial Officer & Senior Vice President at Onyx Pharmaceuticals, Inc. He is currently the Chief Operating Officer & Executive Vice President at Sangamo Therapeutics, Inc. from 2020 to 2024.
McClung completed his undergraduate degree from York University and the University of Guelph.
He also completed an undergraduate degree from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/11/2023 | 111 397 ( 0,05% ) | 56 033 $ | 30/04/2024 |
Anciens postes connus de Mark McClung
| Sociétés | Poste | Fin |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Directeur des opérations | 02/01/2024 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | - |
Formation de Mark McClung
| University of Guelph | Undergraduate Degree |
| York University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |